[Pharmacological study of pipratecol (JP 711) and of a pharmaceutical combination raubasine-JP 711].
D000818:Animals; D001158:Arteries; D001341:Autonomic Nervous System / Q000187:drug effects*; D001775:Blood Circulation / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D002319:Cardiovascular System / Q000187:drug effects*; D002415:Cats; D002490:Central Nervous System / Q000187:drug effects*; D004285:Dogs; D004357:Drug Synergism; D004837:Epinephrine / Q000037:antagonists & inhibitors; D005260:Female; D006168:Guinea Pigs; D006339:Heart Rate / Q000187:drug effects; D006571:Heterocyclic Compounds / Q000494:pharmacology* / Q000633:toxicity*; D006634:Histamine H1 Antagonists / Q000494:pharmacology; D066298:In Vitro Techniques; D008297:Male; D051379:Mice; D009119:Muscle Contraction / Q000187:drug effects; D010101:Oxygen Consumption / Q000187:drug effects; D011817:Rabbits; D051381:Rats; D012039:Regional Blood Flow / Q000187:drug effects; D012119:Respiration / Q000187:drug effects; D046948:Secologanin Tryptamine Alkaloids / Q000494:pharmacology* / Q000633:toxicity*; D013268:Stimulation, Chemical; D009435:Synaptic Transmission / Q000187:drug effects; D013997:Time Factors; D014655:Vascular Resistance / Q000187:drug effects; D014680:Veins
D006571:Heterocyclic Compounds; D006634:Histamine H1 Antagonists; D046948:Secologanin Tryptamine Alkaloids; D004837:Epinephrine
Etude pharmacologique de Pipratecol (JP 711) et d'une association medicamenteuse Raubasine-JP 711.